Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06451198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Study acronym: OPTION2
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Feb 25, 2026 to May 19, 2025v4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Primary completion date: May 31, 2026 to Dec 31, 2028
    • Start date: Jul 1, 2024 to Feb 25, 2026
    • Study sites: 0 to 1
    • Study completion date: May 31, 2027 to Dec 31, 2028
    • Eligibility criteria revised
  3. Start date: Jun 1, 2024 to Jul 1, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.
Trial Details
NCT Number NCT06451198
Lead Sponsor Shanghai Zhongshan Hospital
Conditions
(from sponsor)		 Coronary Artery Disease, Antiplatelet Drugs
Related terms Coronary Artery Disease
Enrollment 2,846 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov